Eli Lilly increases manufacturing investment to $9bn at new Indiana site

Betsy Goodfellow | May 28, 2024 | News story | Manufacturing and Production |  Diabetes, Eli Lilly, Indiana, investment, manufacturing 

Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with a new $5.3bn investment, totalling its investment at this site to $9bn from its original $3.7bn.

The expansion is intended to increase the company’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injections for the treatment of more adults with chronic diseases such as obesity and type 2 diabetes.

David A Ricks, Eli Lilly’s chair and chief executive officer at Eli Lilly, commented: “Today’s announcement tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in US history. This multi-site campus will make our latest medicines, including Zepbound and Mounjaro, support pipeline growth and leverage the latest technology and automation for maximum efficiency, safety and quality control. Importantly, we are investing in our home state of Indiana, creating high-wage, advanced manufacturing, engineering and science jobs for hundreds of current and future Hoosier families.”

Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added: “Lilly’s commitment to meeting the demand for our life-changing medicines goes beyond buildings and extends to improving education opportunities and upskilling a global workforce of the future. Academia is a critical partner to both industry and government as we work together to advance innovation in our state and communities around the globe.”

Betsy Goodfellow